Top Banner
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part A – AD definition, neuropath? NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D. Clinical Professor (affiliated), Department of Psychiatry and Behavioral Sciences Senior Research Scientist, Stanford / VA Aging Clinical Research Stanford University and VA Palo Alto Health Care System January 5, 2010 Slides at: www.medafile.com (Dr. Ashford’s lectures)
18

NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

Mar 21, 2016

Download

Documents

baird

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part A – AD definition, neuropath?. NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D. Clinical Professor (affiliated), Department of Psychiatry and Behavioral Sciences - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND

DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE?

Part A – AD definition, neuropath? NUCLEAR MEDICINE GRAND ROUNDS

Stanford University

J. Wesson Ashford, M.D., Ph.D.

Clinical Professor (affiliated), Department of Psychiatry and Behavioral SciencesSenior Research Scientist, Stanford / VA Aging Clinical Research

Stanford University and VA Palo Alto Health Care System

January 5, 2010

Slides at: www.medafile.com (Dr. Ashford’s lectures)

Page 2: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

Dementia Definition• Multiple Cognitive Deficits:

– Memory dysfunction• especially new learning, a prominent early symptom

– At least one additional cognitive deficit• aphasia, apraxia, agnosia, or executive dysfunction

• Cognitive Disturbances:– Sufficiently severe to cause impairment of occupational or

social functioning and – Must represent a decline from a previous level of functioning

Page 3: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

Alzheimer’s Disease

• First described by Alois Alzheimer, a German neuropathologist, in 1906/7

• Observed in a 51-year-old female patient with paranoia, memory loss, disorientation, and hallucinations

• Postmortem studies characterized senile plaques and neurofibrillary tangles (NFTs) in the cerebral cortex

– Senile plaques: Extracellular accumulation of insoluble fragments of beta-amyloid (A1-42)

– NFTs: Intracellular accumulation of hyperphosphorylated tau strands

Page 4: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

A. Memory Impairment 1. Multiple Cognitive Deficits 2. Other Cognitive Impairment

B. Deficits Impair Social/Occupational FunctionC. Course Shows Gradual Onset and DeclineD. Deficits Are Not Due to:

1. Other CNS Conditions2. Substance Induced Conditions

E. Do Not Occur Exclusively during DeliriumF. Not Due to Another Psychiatric Disorder

Diagnostic Criteria For Dementia Of The Alzheimer Type (DSM-IV, APA, 1994)

Page 5: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

Reprinted with permission from Brumback, RA, Leech RW, J. Ohio State Med Assoc. 1994: 87, 103-111

Page 6: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Age

Perc

enta

ge ADMCINon-Affected

Yesavavage et al., 2002

Page 7: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

Normal Brain Alzheimer Brain

Page 8: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.
Page 9: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.
Page 10: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.
Page 11: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

Cholinergic Changes in AD - 1976• The most prominent neurotransmitter

abnormalities are cholinergic– Reduced activity of choline acetyltransferase

(synthesis of acetylcholine)1

• Reduced number of cholinergic neurons in late AD (particularly in basal forebrain)2

• Selective loss of nicotinic receptor subtypes in hippocampus and cortex1,3

1. Bartus RT et al. Science. 1982;217:408-414. 2. Whitehouse PJ et al. Science. 1982;215:1237-1239. 3. Guan ZZ et al. J Neurochem. 2000;74:237-243.

Page 12: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

Cortex(glutamate neurons)

Specific groups of cholinergic, serotonergic, and noradrenergic that project to the cortex, and glutamatergic neurons of discrete cortical regions are selectively affected in Alzheimer’s disease

Page 13: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

Brun & Englund, 1986

Discrete regions of the cerebral cortex are selectively affected by Alzheimer pathology

Page 14: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

Braak & Braak, 1991; Braak et al., 2006

Page 15: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

(Braak & Braak, 1991)

Page 16: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.
Page 17: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

Braak & Braak, 1991

Page 18: NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

Tangle (NFT) & Plaque (NP)Tangle (NFT) & Plaque (NP)Distribution In AD at AutopsyDistribution In AD at Autopsy

NFT

NP

S. Arnold, Cortex, 1991S. Arnold, Cortex, 1991